Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
Shailesh Jejurikar, Chief Operating Officer of Procter & Gamble Co (PG), reported a sale of 3,986 shares of common stock on
The Form 4 was signed by an attorney-in-fact on
Jennifer L. Davis, an officer (CEO - Health Care) of Procter & Gamble Co (PG), reported a sale of 3,227 shares of common stock on
The sale is described as a routine disposition to satisfy taxes tied to equity compensation rather than an open-market divestiture for liquidity. The form is signed by an attorney-in-fact and reports the transaction under Section 16 rules for insiders.
Insider sale to cover taxes following RSU settlement: An officer of Procter & Gamble (PG) reported a disposition of 3,535 shares of common stock on
The filing states the shares were sold to cover tax obligations upon settlement of a Restricted Stock Unit award, and the Form 4 was signed by an attorney-in-fact on
Susan Street Whaley, Chief Legal Officer & Secretary of Procter & Gamble Co (PG), reported an insider sale on
After the transaction, Ms. Whaley beneficially owned 31,769.8354 shares directly and an additional 6,531.6011 shares indirectly through a retirement plan trustee. The Form 4 was signed by an attorney-in-fact on
Susan Street Whaley, Chief Legal Officer & Secretary of Procter & Gamble Co (PG), reported insider acquisitions on 10/01/2025. She acquired 5,742 shares through restricted stock units awarded under the company plan and recorded 26,531 stock option rights with an exercise/conversion price of $153.18, exercisable beginning 09/29/2028 and expiring 10/01/2035. After the transactions, Ms. Whaley beneficially owns 34,177.8354 shares directly and 6,531.6011 shares indirectly through a retirement plan trustee. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Raman Sundar G., listed as CEO-Fabric & Home Care at Procter & Gamble Co (PG), filed a Form 4 reporting transactions dated 10/01/2025. The filing shows a disposition of 41,886.4892 shares of common stock and an indirect beneficial ownership interest of 8,436.9135 shares held by a retirement plan trustee.
The filing also reports a derivative transaction dated 10/01/2025 labeled as an acquisition: a stock option with a $153.18 exercise/conversion price tied to 68,869 underlying common shares (listed as 68,869 shares beneficially owned following the transaction). An explanatory note states this reflects an adjustment to PST through September 30, 2025. The form is signed by an attorney-in-fact on 10/02/2025.
Gary A. Coombe, identified as CEO - Grooming and an officer of Procter & Gamble Co (PG), reported transactions on 10/01/2025. He was awarded 3,373 Restricted Stock Units under the 2019 Stock and Incentive Compensation Plan, increasing his direct beneficial ownership to 38,351.145 shares. The filing also shows indirect holdings of 481.8949 shares via a retirement plan trustee and 1,295.35 shares through an International Stock Ownership & Pension Plan (Switzerland). In derivatives, Mr. Coombe acquired 46,754 stock options with an exercise price of $153.18, exercisable beginning 09/29/2028 and expiring 10/01/2035. The form was signed by Wednesday Shipp as attorney-in-fact on 10/02/2025.
Ma. Fatima Francisco, an officer at Procter & Gamble Co (PG), reported transactions dated 10/01/2025. The filing shows a disposition of 27,295.0856 shares of Common Stock and an acquisition via option exercise of 62,338 shares (stock option with exercise price $153.18), resulting in 62,338 shares held directly after the exercise. Post-transaction indirect holdings include 15,998.3673 shares held by a retirement plan trustee and 2,862.8125 shares held indirectly by spouse and plan trustees. The form includes an explanatory note that the figures reflect an adjustment to PST through September 30, 2025. The report is signed by an attorney-in-fact on 10/02/2025.
Jennifer L. Davis, listed as CEO - Health Care at Procter & Gamble (PG), reported transactions dated 10/01/2025. The Form 4 shows a disposition of 64,990.9326 shares of common stock and an indirect holding of 15,535.3029 shares held by a retirement plan trustee. The filing also reports an acquisition of 68,869 stock options at an exercise price of $153.18; those options are listed as exercisable beginning 09/29/2028 with an expiration date of 10/01/2035.
The form includes an explanatory note that the indirect amount reflects an adjustment to the participant service trust through 09/30/2025. The document is signed on behalf of Ms. Davis by an attorney-in-fact on 10/02/2025. All items reported are changes in beneficial ownership as required under Section 16.
Matthew W. Janzaruk, SVP and Chief Accounting Officer of Procter & Gamble Co (PG), reported transactions dated 10/01/2025. He exercised_stock_options to acquire 13,779 shares (stock option exercise price $153.18) and directly holds those 13,779 shares following the exercise. The Form 4 also shows a sale of 1,703.9031 shares on the same date and reports 3,293.5342 shares beneficially owned indirectly via a retirement plan trustee after an adjustment through 9/30/2025. The filing was signed by an attorney-in-fact on 10/02/2025. The report is an insider disclosure of option exercise, a small open-market sale, and an adjustment to retirement-plan holdings; it contains transaction dates, amounts, and the exercise price but no cash proceeds or reasons for the transactions.
FAQ
What is the current stock price of Procter & Gamble (PG)?
What is the market cap of Procter & Gamble (PG)?
